Humanized anti-IL-20 antibody and uses thereof

Inventors

Chang, Ming-Shi • Tsurushita, Naoya • Kumar, Shankar

Assignees

Lbl Biotechnology Inc • JN Biosciences LLC

Abstract

Humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.

Core Innovation

The patent discloses humanized anti-interleukin 20 (IL-20) antibodies and associated nucleic acids that bind human IL-20. The humanized antibodies include heavy chain variable region (VH) and light chain variable region (VL) design criteria using SEQ ID sequences, with VH containing the same heavy chain complementary determining regions (CDRs) as those in SEQ ID NO:1 and being at least 90% identical to SEQ ID NO:1 or SEQ ID NO:3, and VL containing the same light chain CDRs as those in SEQ ID NO:5 and being at least 90% or 95% identical to SEQ ID NO:5 or SEQ ID NO:7, with an additional sequence option SEQ ID NO:15 described in the disclosure.

The disclosure further covers isolated nucleic acids encoding VH and VL, vectors including expression vectors with promoter-linked operable linkage, host cells containing such vectors, and therapeutic use via pharmaceutical compositions. Sequence referencing for CDR mapping and signal peptide arrangement is described, and the patent identifies antibody format coverage including IgG, Fab, F(ab’)2, Fv, and single-chain antibody, and mentions the possibility of bi-specific antibodies.

Example binding and biological efficacy data are reported for the parent antibody and humanized antibodies HL1 and HL2, including BIOCORE binding affinity measurements and an osteoclast differentiation/TRAP assay in which HL2 inhibits osteoclast differentiation comparably to the parent antibody. A reported unexpectedly high IL-20 affinity is stated for the disclosed antibodies.

Claims Coverage

The consolidated content includes three independent claims directed to isolated nucleic acids encoding humanized anti-IL-20 heavy-chain variable region, isolated nucleic acids encoding humanized anti-IL-20 light-chain variable region, and a method for producing a humanized antibody by culturing host cells and isolating the antibody. Across these claims, the core inventive features are preserved CDRs from SEQ ID reference sequences and sequence-identity constraints applied to VH and VL, with production features tied to host-cell expression and antibody isolation.

Overall, the claim coverage centers on humanized anti-IL-20 antibody variable regions defined by specific preserved CDRs (SEQ ID NO:1 for VH and SEQ ID NO:5 for VL) and identity thresholds, together with production by culturing expression-vector-bearing host cells followed by isolating the produced humanized antibody.

Stated Advantages

Documented Applications